← All trials
NCT03821857
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 27, 2019
- Primary completion
- May 31, 2024
- Completion date
- May 31, 2024
- First posted
- Jan 30, 2019
- Last posted
- Jun 6, 2023
- Enrollment
- 200
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Mayo ClinicLead sponsor
- Mayo ClinicOverall official - principal investigator
- Mayo ClinicReponsible party - principal investigator
- National Institute on Aging (NIA)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.